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Abstract

We propose a Phase I clinical trial design that seeks to determine the cumulative
safety of a series of administrations of a fixed dose of an investigational agent. In
contrast to traditional Phase I trials that are designed to solely find the maximum
tolerated dose (MTD) of the agent, our design instead identifies a maximum tolerated schedule (MTS) that includes an MTD as well as a vector of recommended
administration times. Our model is based upon a non-mixture cure model that
constrains the probability of toxicity for all subjects to monotonically increase
with both dose and the number of administrations received. We assume a specific
parametric hazard function for each administration and compute the total hazard
of toxicity for a schedule as a sum of individual administration hazards. Throughout a variety of settings motivated by an actual study in allogeneic bone marrow
transplant recipients, we demonstrate that our approach has excellent operating
characteristics and performs as well as the only other currently published design
for schedule-finding studies. We also present arguments for the preference of our
non-mixture cure model over the existing model.
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S UMMARY
We propose a Phase I clinical trial design that seeks to determine the cumulative
safety of a series of administrations of a fixed dose of an investigational agent. In
contrast to traditional Phase I trials that are designed to solely find the maximum
tolerated dose (MTD) of the agent, our design instead identifies a maximum tolerated schedule (MTS) that includes an MTD as well as a vector of recommended
administration times. Our model is based upon a non-mixture cure model that
constrains the probability of toxicity for all subjects to monotonically increase
with both dose and the number of administrations received. We assume a specific
parametric hazard function for each administration and compute the total hazard
of toxicity for a schedule as a sum of individual administration hazards. Throughout a variety of settings motivated by an actual study in allogeneic bone marrow
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transplant recipients, we demonstrate that our approach has excellent operating
characteristics and performs as well as the only other currently published design
for schedule-finding studies. We also present arguments for the preference of our
non-mixture cure model over the existing model.
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1. Introduction
Conventional Phase I clinical trials have been designed for the sole purpose of
identifying a maximum tolerated dose (MTD) based upon a single administration.
However, in many clinical settings, the agent will be given repeatedly over a sequence of administrations and patients will be followed to assess the cumulative
safety of the agent. As a result, treatment is two dimensional, consisting not only
of the dose given at each administration, but also the timing of each administration.
Braun et al. (2003) applied the Time-to-Event Continual Reassessment Method
(TITE-CRM) of Cheung and Chappell (2000) by attempting to model each schedule of administrations as a “dose.” Due to the limitations of this approach, Braun
et al. (2005) presented the first design specifically created to determine a maximum tolerated schedule (MTS) instead of a traditional MTD. In their approach,
the authors chose to model separately the hazards of toxicity for the individual administrations in a schedule. It is reasonable to assume that the hazard of toxicity
for many cytotoxic agents increases steadily after administration, reaches a peak,
and then begins to decrease as the agent is cleared from the patient. For simplicity,
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Braun et al. (2005) adopted a piecewise linear model

u
0 ≤ u ≤ θ1

 θ2 θ1



−u
h(u | θ) =
θ1 < u ≤ θ3
θ2 θθ33−θ
1





0
u > θ3 or u < 0

(1)

in which θ = (θ1 , θ2 , θ3 ), with θ1 the time at which h(u | θ) reaches its maximum,
θ2 the maximum hazard, and θ3 the time when the hazard vanishes to zero. Using
this hazard for each administration, the total hazard for a series of administrations
was modeled simply as the sum of the hazards of each administration. Given
the timing of each administration, the total hazard implies a cumulative hazard
and cumulative probability for toxicity at any point in time. Thus, the outcome
of interest in this design is the time to toxicity, rather than a binary indicator
of toxicity ever occurring. Subject accrual, Bayesian estimation, and outcomeadaptive decision-making are done in a sequential fashion as in classical Phase I
trial designs.
Even though Braun et al. (2005) demonstrated the triangle hazard model performed well in the scenarios they investigated, there are several aspects of this
hazard model that could be improved. First, none of the parameters in θ have interpretations that relate directly to the overall probability of toxicity. Second, the
hazard function in Equation (1) is not smooth due to the abrupt change in slope
at θ1 , i.e θ1 is a change-point for the hazard, and maximum likelihood estimation
of θ1 is difficult (Liu, 2007). Third, the hazard is truncated at θ3 , which conflicts
with the usual approach in time-to-event modeling of assuming an infinite support
of toxicity times for the hazard. Finding a maximum likelihood estimate (MLE)
of θ3 is also computationally challenging as truncation parameters do not share
the regularity characteristics common to most parameters. Fourth, the model is
3
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inflexible for the inclusion of subject-level or administration-level covariates, i.e.
if the dose were to vary with each administration. Although the triangular hazard
was generalized to incorporate varying doses, the approach used required a different value of θ for each dose, forcing the total number of parameters to increase
rapidly as more doses are studied (Braun et al., 2007). Although one could conceive of a regression model for each parameter in θ as a function of subject-level
covariates, the direct relationship of each covariate to the probability of toxicity
would be difficult or impossible to discern.
As an alternative to the method of Braun et al. (2005), we propose a parametric non-mixture cure model for determining the MTS. Through this approach, we
model the cure fraction and marginal probability of toxicity directly as a function
of the number of administrations. Most importantly, this model includes parameters whose values can be directly interpreted in relationship to the probability
of toxicity. We continue with the approach of Braun et al. (2005) and model
the total hazard of toxicity as a sum of single administration hazards. However,
due to the limitations described earlier, we instead choose to model the hazard
for each administration to be proportional to a standard two-parameter Weibull
density function. Given the flexibility of the shape of this density, our model can
accommodate a variety of hazard functions beyond the “up-and-down” triangular
hazard if so desired. In Section 2, we describe basic notation and develop our
parametric cure model. Section 3 contains a method for developing prior distributions for our parameters, and Section 4 contains a specific outline of trial conduct
using our design. Section 5 describes the performance of our algorithm and compares it to the approach of Braun et al. (2005). Section 6 contains concluding
remarks.
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2. Notation and Cure Model Development
2.1 Notation
We have K treatment schedules, s(1) , s2 , . . . , s(K) under investigation in a
trial. Schedule k has a total of mk administrations and s(k) is a vector of planned
administration times, i.e. s(k) =(s1 , s2 , ..., smk ). Furthermore, s(k) is nested in
s(k+1) for each k = 1, ..., K − 1, so that the duration of a treatment schedule
increases with k and m1 < m2 < ... < mK . For example, if the first schedule
was comprised of three weekly administrations after enrollment and the second
schedule was a three-week extension of the first schedule, s(1) = {0, 7, 14} and
s(2) = {0, 7, 14, 21, 28, 35} = {s(1) , s(1) + 21}. Let ω denote the fixed maximum
length of follow-up for each subject, defined by the medical investigators as a
clinically meaningful endpoint that is also late enough to accommodate the longest
schedule, s(K) . For example, in toxicity studies of possible treatments for acute
graft-versus host disease (aGVHD) in allogeneic bone marrow transplant patients,
ω is often set at 100 days, as this is the the duration of time required for aGVHD to
develop. A fixed target probability pω is elicited from investigators and is defined
as the target cumulative probability of toxicity by time ω.
A maximum of N subjects will be enrolled in the study, each observed to
the earlier of toxicity or completing ω days of follow-up without toxicity. We
assume that entry of the first subject coincides with day t∗1 = 0 of the trial, while
t∗j denotes the duration of the study when each successive subject j = 2, 3, . . . , N
is enrolled. The shortest schedule is assigned to the first subject, and the schedule
assigned to each successive subject j is determined through an interim analysis at
time t∗j using the data from previously enrolled subjects i = 1, 2, . . . , j − 1. We
let Ti denote the actual, possibly unobserved, time after enrollment for subject i.
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At interim evaluation time t∗j , we let Ui denote the length of follow-up for subject
i, i < j, i.e. Ui = min(Ti , t∗j − t∗i ), and Ci is the indicator of whether or not Ui
corresponds to a toxicity i.e.

Ci =

1 ; Ti = Ui ,
0 ; Ti 6= Ui .

We emphasize that the study is designed ideally so that each subject will receive a series of administrations at specific, fixed administration times as defined
by s(1) , ..., s(K) . However, in practice, subjects may deviate from their assigned
schedule after they begin treatment for a host of reasons, including clinician error
or delay of treatment for medical reasons unrelated to toxicity, such as infection.
Therefore, we let si = {si,1 , ..., si,mi } denote the actual times after enrollment at
which subject i receives an administration, where si,1 coincides with enrollment
and mi is the number of administrations received. Although mk administrations
are planned for subjects assigned to schedule s(k) , it may be the case that mi < mk
either due to administrative censoring or because subject i had toxicity at time
si,mi and thus received no further administrations.
2.2

Model Development
Consider a parametric probability density function (pdf) f (u | φ) consisting

of parameters φ, with cumulative distribution function F (u | φ). We then model
the hazard of toxicity for each administration using a scaled form of the density
h(u | φ, θ) = θf (u | φ), where θ > 0 is an additional parameter quantifying
the proportionality of h(·) to f (·). As a result, each administration has a survival
function equal to
S(u | φ, θ) = exp{−θF (u | φ)}

(2)
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that is improper in the sense that S(∞) = exp{−θ} > 0. Such a model is known
as a non-mixture cure model with cure rate exp{−θ}; see Chen et al. (1999) and
Tsodikov et al. (2003) for detailed descriptions. In the context of Phase I trials,
the probability of toxicity is 1 − exp{−θ}.
We emphasize that the concept of a cure fraction is appealing in Phase I trials, as we expect a proportion of subjects to never experience toxicity, even with
infinite follow-up. Unlike our proposed model, the cure fraction was not directly
parameterized in Braun et al. (2005) and was instead implied through the finite
duration of the hazard θ3 in Equation (1). Another benefit of our approach over
that in Braun et al. (2005) is that the single-administration hazard h(u | φ, θ)
can be quite general, provided that it is biologically plausible and is sufficiently
tractable for parameter estimation. Most importantly, the hazard is not restricted
to have an up-and-down pattern nor have finite support like that in Braun et al.
(2005).
Thus, we recommend the hazard be based upon a two-parameter Weibull density
h(u | φ, θ) = θ exp(−γ)αuα−1 exp[−uα exp(−γ)]

(3)

in which φ = (α, γ), α > 0 and −∞ < γ < ∞. This function implies a nonmontonic hazard when α ≥ 2, and also allows for a monotonically decreasing
hazard when 0 ≤ α < 2, which may be suitable when the agent is given as a bolus
with immediate exposure to maximum toxicity that then decreases over time. In
our application, we choose to specifically constrain α ≥ 2 so that the resulting
hazard function has our desired non-monotonic pattern. Figure 1 displays an example of such a hazard for α = 2, γ = 4, and θ = 0.3 and demonstrates that
although an infinite support exists for the time to toxicity, the hazard basically
7
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vanishes 20 days after administration.
[Figure 1 about here.]
We assume that the form of h(·) is unchanged among administrations and that
all administrations have an additive cumulative effect on toxicity. Based upon
these assumptions, we generate the total and cumulative hazards of toxicity at a
general study time t∗ for a subject treated with schedule s(k) and follow-up U as
(k)

h(U | φ, θ, s ) = θ(mk )

mk
X

f (U − s` | φ)/mk

(4)

F (U − s` | φ)/mk ,

(5)

`=1

H(U | φ, θ, s(k) ) = θ(mk )

mk
X
`=1

and corresponding survival function
"
S(U | φ, θ, s(k) ) = exp −θ(mk )

mk
X

#
F (U − s` | φ)/mk .

(6)

`=1

In Equations (4)-(6), the parameter θ is now generalized to be a function of
the number of administrations, which is necessary so that the limiting cumulative
probability of toxicity changes with the number of administrations and is equal
to 1 − exp{−θ(mk )}. We have also expressed Equations (4) and (5) as an average of hazards among administrations; if scaling by mk were not done, then
we would have Sk (∞) = exp{−mk θ(mk )}. Instead, scaling by mk maintains
exp{−θ(mk )} as the cure rate for schedule k.
In order to force the cumulative probability of toxicity to increase with the
number of administrations, we adopt the regression model log{θ(mk )} = β0 +
β1 log(mk ), β1 ≥ 0, leading to a cure fraction equal to exp{− exp[β0 +β1 log(mk )]}.
This model also lends to a simple interpretation of β0 as quantifying a single adminstration’s impact on the cure fraction.
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Note that our model assumes that the limiting cumulative probability of toxicity, or conversely the cure fraction, is the same for two subjects receiving the same
number of administrations, regardless of when they receive those administrations.
The administration times only impact the rate at which the limit is reached. Other
models could certainly be adopted that allow the cure fraction to vary by the administration times. Most importantly, our model is much more flexible than that
of Braun et al. (2005) and allows for the inclusion of additional covariates both
in the cure fraction, as well as the hazard function. For example, if dose were to
vary among the subjects, we could directly incorporate dose effects either in the
cure fraction or the hazard function using standard regression models.
For the interim analysis at t∗ , subject i contributes three pieces of data: (1) Ui ,
the length of follow-up, (2) Ci , an indicator of toxicity, and (3) si , a vector of mi
administration times. We let D ∗i = {Ui , Ci , si }, so that the total data collected
on all n∗ subjects at t∗ is D ∗ = {D ∗1 , D ∗2 , . . . , D ∗n∗ }. Using this data, the interim
likelihood for our parameters is
∗

n
Y
L(φ, β | D ) =
{h(Ui | φ, β0 , β1 , si )}Ci S(Ui | φ, β0 , β1 , si )
∗

(7)

i=1

where β = {β0 , β1 } and the survivor and hazard functions are defined in Equations (4) and (6), respectively.
3. Developing Priors for φ and β
Since the sample sizes of most Phase I trials are small and very little information is
available at the beginning of a trial, we choose to use sequential Bayesian methods
to find updated estimates of φ and β. Once we define prior distributions for our
parameters, we use Markov chain Monte Carlo (MCMC) techniques to sample
from the posterior distributions of φ and β. As there are no constraints on γ and
9
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β0 , we assume both are normally distributed with respective means µγ and µβ0
and respective variances σγ2 and σβ20 . To reflect our need for α ≥ 2 so that we
have a non-monotonic hazard, we assume α is equal in distribution to Zα + 2,
where Zα has a Gamma distribution with mean (µα − 2) and variance σα2 . Note
that there is no need to shift the distribution of α if one desires a monotonically
decreasing hazard. To satisfy our constraint β1 > 0, we assume that β1 has a
Gamma distribution with mean µβ1 and variance σβ21 .
To develop mean hyperparameter values for the cure fraction parameters β,
we ask the investigators to specify an a priori value, Pk , for the cumulative probability of toxicity for schedule k, k = 1, 2, . . . , K. Based upon the simple linear
regression model E{log[− log(1 − Pk )]} = b0 + b1 log(mk ), we use ordinary least
squares to find estimates of b0 and b1 . We let µβ0 and µβ1 equal the estimates of
b0 and b1 , respectively. With regard to the hazard shape parameters φ, we ask the
investigators to specify an a priori value for the limiting cumulative probability
of toxicity for a single administration. We denote this value Q0 and note that Q0
must be less than the value of P1 elicited earlier. We also ask investigators to select
two time points t1 and t2 and supply a priori values Q1 and Q2 for the cumulative probabilities of toxicity at t1 and t2 , respectively, for a single administration.
Based upon Equation (2), we first derive the value θ∗ = − log(1 − Q0 ). Plugging
θ∗ and Equation (3) into Equation (2), some algebra gives us two equations in
terms of two parameters a and g:
log{− log[1 + log(1 − Q1 )/θ∗ ]} = a log(t1 ) − g
log{− log[1 + log(1 − Q2 )/θ∗ ]} = a log(t2 ) − g
If we let â and ĝ denote the respective solutions to a and g in the above equations,
10
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we set µα = max{2.01, â} and µγ = ĝ.
We do not derive variance hyperparameter values from elicited information;
we choose rather to treat them as tuning parameters that will determine how informative the priors will be. We run exhaustive simulations using a handful of
subjects and a variety of variance hyperparameter values until “suitable” values
are determined. Specifically, we consider two extreme scenarios: (1) the prior
means indicate that the longest schedule is tolerable, yet the first few subjects experience toxicity after very few administrations, and (2) the prior means indicate
that only the lowest schedule is tolerable, yet the first few subjects fail to experience toxicity after several administrations. Our approach is to first set the prior
variance of each parameter to one-tenth the magnitude of the corresponding prior
mean and run small simulation studies under settings (1) and (2) and continually
modify the variances until we find values that allow the data to override the prior
means in both settings. We also draw 10,000 samples from each of the priors
and plug those values into Equation (6) to generate 10,000 prior estimates of the
probability of toxicity by ω for each schedule k. We then plot histograms of these
values for each schedule k to visually inspect that the distributions have means
tending to increase with mk and with a modest amount of variability around each
of the means. Figure 2 is an example of such a plot in the context of the numerical
examples of Section 5.
4. Trial Conduct
Once suitable prior distributions are selected, we enroll the first subject on the
lowest schedule, s(1) . With each additional subject j = 2, 3, . . . N , the following
procedure is followed:
(1) For each subject i = 1, 2, . . . , j − 1, identify si , the number and timing
11
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of administrations, Ui , the length of follow-up, and Ci , an indicator for the
occurrence of toxicity;
(2) Insert the data into the likelihood in Equation (??) and combine it with the
prior to sample from the posterior distributions of φ = (α, γ) and β =
(β0 , β1 ) using MCMC;
b and β
b into Equation (6) and compute for each
(3) Plug the posterior means φ
b β,
b s(k) ), the estimated probability of toxicity
schedule k, pbk = 1−Sk (ω | φ,
by ω;
(4) Compare all pbk to pω , the target probability of toxicity by ω. Then, determine the schedule k with pbk closest to pω and denote the schedule as k̃;
(5) Let k(j−1) denote the schedule assigned to subject j − 1; assign subject j to
schedule k ∗ = min([k(j−1) + 1], k̃);
(6) Stop treating any subjects i = 1, 2, · · · j − 1 who are still receiving administrations and have received administrations beyond those included in k ∗ ;
(7) Reassign schedule k ∗ to subjects i = 1, 2, · · · j − 1 who are still receiving
administrations and are assigned to a schedule other than k ∗ .
Once all N subjects have been enrolled and fully followed for a maximum of ω
days, the MTS is defined as the schedule satisfying trial conduct rule (4) using the
data of all N subjects.
We now highlight some important aspects in the trial conduct. First, all future
planned treatment for a subject is stopped once a toxicity occurs. Second, conduct
rule (4) uses a criterion, as a function of treatment schedule, that is identical to
12
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the CRM criterion as a function of dose (O’Quigley et al., 1990). If one were
concerned with further limiting the rate of escalation, an alternative criterion proposed in Braun et al. (2005) could be used that reflects the point estimate pbk , as
well as the percentage of its corresponding posterior distribution lying above pω .
One could further modify conduct rule (4) to terminate the study if all pbk were
greater than pω , subject to a minimum accrual requirement. Third, conduct rule
(5) forbids non-incremental schedule escalation, so that each subject can be assigned to at most the next-longest schedule beyond that of the preceding subject.
However, we do not put any constraint on schedule de-escalation, i.e. we enroll
the next subject on the recommended schedule if it is shorter than the schedule
assigned to the preceding subject. Fourth, conduct rules (6) and (7) are implemented to promote patient safety while increasing the likelihood that each patient
is assigned to the actual MTS. Note that this feature of schedule reassignment was
not discussed in the approach of Braun et al. (2005), although such an approach
could be easily implemented.
5. Numerical Studies
We compared the performance of our algorithm with that of Braun et al. (2005)
in a variety of settings via simulations programmed in SAS (SAS Institute Inc.,
Cary, NC, USA). We adopted the motivating example of Braun et al. (2005),
a study in which investigators wished to study K = 6 schedules corresponding
to 2, 4, 6, 8, 10, 12 weeks of therapy. Each week of therapy consisted of three
consecutive daily doses followed by four consecutive days of rest so that schedule
k consisted of mk = 6k administrations. The maximum period to monitor toxicity
was specified to be ω = 100 days. Our goal was to determine how long a subject
could be treated while maintaining the cumulative probability of toxicity by ω to
13
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be as close as possible to the threshold value, pω = 0.40.
We studied the design with a maximum sample size of N = 30 patients, which
is feasible in Phase I trials and one that we have also found is sufficient to determine the MTS with reasonable accuracy. In each simulation, subject interarrival
times were assumed to be uniformly distributed within 12 to 16 days. The first
subject was assigned to the shortest schedule, with subsequent schedule assignments based upon the optimal schedule determined from the methods described
in Section 4. At each interim analysis, a single chain of 5000 observations, after
a burn-in of 1000 observations was drawn from the posterior distribution of each
parameter.
We performed simulations in a series of eight scenarios; the actual probabilities of toxicity within 100 days for each schedule in all scenarios are shown
in Table 1. The first six scenarios correspond to settings in which schedule s(j)
was optimal for scenario j, j = 1, 2, . . . 6 and there is relatively small differential
change in the toxicity probabilities as the schedules increase. The final two scenarios correspond to settings in which there is a large jump in toxicity probabilities
near the MTS; in scenario 7, the true MTS is schedule 3, while in scenario 8 the
MTS lay between schedules 3 and 4. The proximity of toxicity probabilities for
neighboring schedules impacts the ability of any algorithm to identify the target
schedule. Therefore, we quantify the difficulty in identifying the optimal schedule
in each scenario with a measure ∆p , which is the average absolute distance of pω
from the toxicity probabilities. The value of ∆p for each scenario is shown in the
final column of Table 1; smaller values indicate greater difficulty in locating the
MTS. Thus, we predict that the MTS is easier to identify in scenarios 1,2,7, and
8 and harder to identify in scenarios 3-6. In all simulations, toxicity times were
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not simulated under our assumed model; instead, toxicity times were simulated to
occur uniformly over the interval [10 + 14(j − 1), 10 + 14j] under schedule s(j) .
As a result, not only can we directly compare the two approaches, we can also
examine the performance of our algorithm under model misspecification for the
toxicity times.
[Table 1 about here.]
With regard to the prior distributions for φ and β, the investigators supplied
the values P1 = 0.09, P2 = 0.17, P3 = 0.23, P4 = 0.29, P5 = 0.35, P6 = 0.40.
Thus, they believed the longest schedule, s(6) , was optimal, a belief that led to a
misspecified prior for all but the sixth scenario. The investigators also believed
that one administration had a limiting cumulative probability Q0 = P1 /6 (onesixth of the shortest schedule), with corresponding cumulative probabilities of
toxicity Q1 = Q0 /4 and Q2 = Q0 /2 at times t1 = 6 days and t2 = 9 days, respectively. From these elicited values, we used the methods described in Section 3 to
estimate the mean hyperparameter values µα = 2.2, µγ = 0.1, µβ0 = −4.3 and
µβ1 = 1.1. Through a detailed sensitivity analysis, we identified variance hyperparameter values σα = 0.50, σγ = 0.20, σβ0 = 1.2 and σβ1 = 0.3 that allowed for
adequate performance of our algorithm. Figure 2 displays histograms of 10,000
draws from the resulting priors of F (100|φ, θ, s(j) ) for j = 1, . . . , 6. As expected,
the prior for schedule 6 is centered most closely to the target pω = 0.40 and the
centers of the distributions increase with the number of administrations. The prior
distributions used for the triangular model of Braun et al. (2005) were derived as
described in their manuscript, assuming the longest schedule was optimal and one
administration had a hazard of 18 days and a peak at 2 ± 2 days.
15
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[Figure 2 about here.]
The results in Table 2 demonstrate that both approaches do an excellent job
of identifying the MTS even when their corresponding assumed models do not
reflect the actual toxicity times. However, this result is not unexpected, as the
MTS selected at the end of the study is impacted strongly by the overall rate of
toxicity and less so by the actual times of toxicity. The times of toxicity instead
influence the schedule assigned to each subject during the study and influence the
overall percentage of subjects assigned to a neighborhood of the MTS. And with
regard to this latter metric, we see that our approach does a slightly better job in
some scenarios of assigning subjects to schedules close to the MTS. For example,
our approach assigned an average of 55% of subjects within a neighborhood of the
MTS in scenario 2, as compared to 43% with the approach of Braun et al. (2005);
the corresponding percentages in scenario 6 are 60% and 52%, respectively.
However, no clear trend exists as to which approach does a better job of assigning subjects during a study. A worthy area for future research would be to
formally assess whether one approach is more likely than the other to respond to
the actual toxicity times and adjust patient assignments accordingly. Regardless, it
is very encouraging that both approaches perform well in scenarios 7 and 8 when
there is a drastic increase in the risk of toxicity at schedules beyond the true MTS,
even when toxicities have a very late time of onset.
[Table 2 about here.]
6. Conclusion
In this paper, we have proposed a non-mixture cure model to identify an optimal schedule among a fixed number of possible nested treatment schedules. Via
16
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simulation, we have demonstrated the excellent operating characteristics of our
algorithm when the assumed model is misspecified, as well as when the prior is
incorrectly specified. By adopting a cure model framework, we have created a
very flexible design that can be used in a variety of settings and allows for the
adjustment of patient-level characteristics as sample size permits. We want to emphasize that we did not seek to improve the results of Braun et al. (2005), but
rather to develop a more flexible and appealing model for the cumulative hazard
of toxicity. Based upon our arguments in Section 1 and the simulation results in
Section 5, we feel our approach is an extremely useful contribution to the design
of schedule-finding studies.
We have begun to extend our algorithm by including dose as a covariate in our
model for the cure fraction and plan to further examine this algorithm to that proposed in Braun et al. (2007). Our approach would assume proportional hazards
among doses, which may seem overly restrictive to some readers. However, it is
recognized in dose-finding studies that the specific parametric model used is of
mild consequence, as the goal of the design is only to identify the optimal dose
rather than estimate the probability of toxicity across a continuum of doses. A
similar argument can be made for the assumption of proportional hazards, as we
suspect that such an assumption will still lead to correct identification of optimal
dose and schedule combinations with fewer parameters, although not accurately
estimating the probability of toxicity among all dose and schedule combinations.
Nonetheless, we could allow the parameters α and γ to vary by dose if proportional hazards was not a reasonable assumption. We can also easily generalize
our model to allow for hazards that change with each administration by modeling
the hazard parameters as a function of administration number or the time between
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administrations.
Our model can be used for the design of any clinical trial in which investigators wish to measure the impact of multiple administrations on a binary outcome.
Thus, our algorithm could be used in a Phase II study seeking to determine how
many administrations are necessary for a desired rate of efficacy, or in a Phase
III study comparing two different schedules or doses of the same agent or two
different agents in a large sample of (randomized) subjects. Furthermore, if our
methods were applied to a large cohort of subjects like that in a Phase III trial, we
could model the single-administration hazard non-parameterically with standard
techniques rather than forcing a parametric pattern on the event times.
We could also extend our models to allow for optimal treatment schedule finding with combinations of two agents where both agents have a multiple treatment
schedule. In this scenario, our outcome remains the time to toxicity; however, the
non-mixture cure model would incorporate main effects of both agents into the
cure fraction, as well as a term for any possible interaction between the agents.
The more challenging aspect of this design is how to incorporate both agents into
the time to toxicity hazard, as the two agents will likely differ in both the number
of administrations, as well as the times of administration. Nonetheless, once we
have a reasonable model, the Bayesian estimation procedures developed in this
paper could be used in the design for evaluating the combination therapies.
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Figure 1. Visual representation of single administration hazard based upon Equation (3) with α = 2, γ = 4, and θ = 0.3.

20
http://biostats.bepress.com/umichbiostat/paper80

Schedule 1

Schedule 2

Median=0.08

0.0

0.2

0.4

0.6

0.8

Median=0.15

1.0

0.0

0.2

Schedule 3

0.4

0.2

0.4

0.6

0.8

1.0

0.0

0.2

0.4

0.4

0.6

0.6

0.8

1.0

Schedule 6

Median=0.34

0.2

1.0

Median=0.28

Schedule 5

0.0

0.8

Schedule 4

Median=0.22

0.0

0.6

0.8

Median=0.39

1.0

0.0

0.2

0.4

0.6

0.8

1.0

Figure 2. Empirical prior distributions for cumulative probability of toxicity by
day 100 for each schedule. Solid vertical line represents median.
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Table 1
Numeric description of scenarios 1-8

Scenario
1
2
3
4
5
6
7
8

1
0.40
0.23
0.16
0.12
0.10
0.08
0.10
0.20

Probability of DLT by ω
2
3
4
5
0.64 0.79 0.87 0.92
0.40 0.54 0.64 0.72
0.29 0.40 0.49 0.57
0.23 0.32 0.40 0.47
0.19 0.26 0.34 0.40
0.16 0.23 0.29 0.35
0.20 0.30 0.60 0.70
0.30 0.40 0.70 0.80

6
0.95
0.79
0.64
0.54
0.46
0.40
0.80
0.90

∆p
0.36
0.21
0.14
0.12
0.13
0.15
0.25
0.25
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Table 2
Comparison of proposed design to that of Braun,et al (2005) with an incorrectly
specified model. For each scenario, each entry is the percentage of simulations in
which each schedule was chosen as optimal, with the average percentage of
patients assigned to each schedule in parentheses. Line A corresponds to the
results using the proposed model; Line B corresponds to the results using
Braun,et al (2005). Boldfaced values correspond to schedules within a 10 point
neighborhood of pω = 0.40

Scenario
1

Method
(A)
(B)

1 (2)
90 (60)
88 (58)

Schedule (number of weeks)
2 (4)
3 (6)
4 (8) 5 (10)
9 (26)
1 (9)
0 (3)
0 (2)
12 (33)
0 (6)
0 (2)
0 (1)

2

(A)
(B)

29 (33)
25 (20)

61 (55)
60 (43)

8 (10)
15 (24)

2 (1)
0 (8)

0 (1)
0 (3)

0 (0)
0 (2)

3

(A)
(B)

9 ( 7)
8 (14)

25 (25)
29 (23)

41 (24)
45 (32)

19 (22)
16 (18)

6 (14)
2 ( 9)

0 (8)
0 (3)

4

(A)
(B)

4 (10)
3 ( 9)

20 (18)
18 (17)

27 (22)
23 (18)

32 (26)
34 (28)

14 (13)
15 (16)

3 (9)
7 (11)

5

(A)
(B)

0 (3)
0 (2)

4 ( 4)
2 (14)

19 (23)
22 (22)

26 (30)
27 (20)

34 (25)
33 (28)

17 (15)
16 (14)

6

(A)
(B)

0 (2)
0 (3)

0 ( 4)
0 (11)

11 ( 9)
12 (16)

22 (25)
20 (18)

27 (28)
25 (22)

40 (32)
43 (30)

7

(A)
(B)

10 ( 9)
4 (11)

25 (25)
37 (27)

37 (28)
41 (36)

20 (15)
13 (13)

6 (11)
4 ( 7)

2 (10)
1 ( 6)

8

(A)
(B)

2 (2)
6 (5)

27 (25)
30 (24)

41 (30)
42 (33)

19 (24)
13 (19)

9 (11)
8 (11)

2 (6)
1 (8)

6 (12)
0 (0)
0 (0)
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